Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹32,644 Cr revenue.
COGS 30.6%, employees 17.1%.
“reporting a 4.”
“next two years, we will absolutely get back to, to the growth and to the margins.”
“very comfortable with the 15% plus.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 15.5%▲ | 10.5% |
| ROCE | 19.1%▲ | 13.8% |
| Net Margin | 15.4%▲ | 8.7% |
| EBITDA Margin | 26.3%▲ | 16.0% |
| Debt To Equity | 0.12x▼ | 0.21x |
| Rev Growth 3yr | 15.3%▲ | 5.8% |
| EPS Growth 3yr | 37.2%▲ | 3.6% |
Historical valuation data not available.
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹34,682 Cr +6.2% | ₹32,644 Cr +16.5% | ₹28,011 Cr +13.5% | ₹24,670 Cr +14.5% | ₹21,545 Cr +13.1% | ₹19,048 Cr +8.7% | ₹17,517 Cr +13.4% | ₹15,448 Cr |
| Other Income | ₹1,405 Cr +28.1% | ₹1,097 Cr +22.7% | ₹894 Cr -15.3% | ₹1,056 Cr +117.9% | ₹484 Cr +66.2% | ₹291 Cr -53.0% | ₹621 Cr +83.9% | ₹338 Cr |
| Total Income | ₹36,087 Cr +7.0% | ₹33,741 Cr +16.7% | ₹28,905 Cr +12.4% | ₹25,725 Cr +16.8% | ₹22,030 Cr +13.9% | ₹19,339 Cr +6.6% | ₹18,138 Cr +14.9% | ₹15,786 Cr |
| COGS | ₹11,877 Cr +19.0% | ₹9,980 Cr +21.6% | ₹8,209 Cr +7.2% | ₹7,658 Cr +2.9% | ₹7,442 Cr +22.4% | ₹6,079 Cr +9.4% | ₹5,554 Cr +23.6% | ₹4,495 Cr |
| ₹28,903 Cr +10.8% | ₹26,083 Cr +20.1% | ₹21,719 Cr +10.2% | ₹19,714 Cr +3.5% | ₹19,039 Cr +15.4% | ₹16,503 Cr +1.2% | ₹16,308 Cr +20.9% | ₹13,494 Cr | |
| Profit Before Tax | ₹7,184 Cr -6.2% | ₹7,658 Cr +6.6% | ₹7,186 Cr +19.5% | ₹6,012 Cr +101.0% | ₹2,991 Cr +5.5% | ₹2,836 Cr +55.0% | ₹1,830 Cr -20.2% | ₹2,292 Cr |
| ₹1,675 Cr -14.3% | ₹1,954 Cr +20.4% | ₹1,623 Cr +5.3% | ₹1,541 Cr +75.4% | ₹879 Cr -5.7% | ₹932 Cr ↑ Recovery | (₹140 Cr) ↓ Decline | ₹386 Cr | |
| Net Profit | ₹5,523 Cr -3.5% | ₹5,725 Cr +2.6% | ₹5,578 Cr +23.8% | ₹4,507 Cr +106.5% | ₹2,183 Cr +11.8% | ₹1,952 Cr -3.7% | ₹2,026 Cr +3.9% | ₹1,950 Cr |
| Profit (Owners) | ₹5,568 Cr -1.5% | ₹5,655 Cr +1.4% | ₹5,578 Cr +23.8% | ₹4,507 Cr +106.5% | ₹2,183 Cr +11.8% | ₹1,952 Cr -3.7% | ₹2,026 Cr +3.9% | ₹1,950 Cr |
| Minority Interest | (₹45 Cr) ↓ Decline | ₹70 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹603 Cr +194.3% | ₹205 Cr ↑ Recovery | (₹66 Cr) -442.1% | (₹12 Cr) +95.8% | (₹290 Cr) ↓ Decline | ₹540 Cr ↑ Recovery | (₹65 Cr) +40.2% | (₹109 Cr) |
| EPS | ₹66.72 | ₹67.77 | ₹66.87 | ₹54.13 | ₹26.23 | ₹23.47 | ₹24.38 | ₹23.48 |
| Diluted Shares | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr |
| Profit Or Loss Of Associates | ₹14 Cr -34.1% | ₹22 Cr +47.6% | ₹15 Cr -60.3% | ₹37 Cr -47.4% | ₹70 Cr +46.5% | ₹48 Cr -14.4% | ₹56 Cr +28.1% | ₹44 Cr |
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 13, 2026, titled "Dr. Reddy s announces the first-to-market launch of Bosutinib Tablets 400mg, a generic ...
Dr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Kallam Satish Reddy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation...
Dr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meet
Dr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock Options
Dr. Reddy's Laboratories Limited has informed the Exchange about Schedule of Analyst/Investor meet
Dr. Reddy's Laboratories Limited has informed the Exchange about
Dr. Reddy's Laboratories Limited has informed the Exchange that the Annual Report in Form 20F for the fiscal year ended March 31, 2026 has been filed with United States Securities and Exchange Commiss...
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Dr. Reddy's Laboratories to Ring the Closing Bell® at the New York Stock Exchange.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada".
Dr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Dr. Reddy's Laboratories Limited has informed the Exchange that Record date for the purpose of Final Dividend is 10-Jul-2026.
Dr. Reddy's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2026, recommended Final Dividend of Rs. 8 per equity share.
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Dr. Reddy's Laboratories Limited has informed the Exchange about Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals